Eric Spronz
Psychiatric/Mental Health · Centereach, NYNPI 1922332261
Payments from drug & device makers
Across 1,015 payments — averaging $441.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$411K
- Otsuka America Pharmaceutical, Inc.$16K
- AbbVie$9K
- E.r. Squibb & Sons, L.L.C.$5K
- Acadia Pharmaceuticals Inc$1K
- Lundbeck LLC$871
- plus $5K from 22 others
What the payments were for
- Consulting fees$32,4817%
- Speaking & faculty fees$359,20280%
- Travel & lodging$32,9487%
- Food & beverage$23,2555%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 545 | $411,181 |
| Otsuka America Pharmaceutical, Inc. | 82 | $16,179 |
| AbbVie | 105 | $8,908 |
| E.r. Squibb & Sons, L.L.C. | 24 | $4,771 |
| Acadia Pharmaceuticals Inc | 46 | $1,033 |
| Lundbeck LLC | 49 | $871 |
| Harmony Biosciences LLC | 30 | $806 |
| Alkermes, Inc. | 19 | $786 |
| Axsome Therapeutics, Inc. | 18 | $677 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $438 |
| Kyowa Kirin, Inc. | 10 | $351 |
| Janssen Scientific Affairs, LLC | 2 | $230 |
| Biogen | 2 | $215 |
| Avanir Pharmaceuticals, Inc. | 12 | $210 |
| Teva Pharmaceuticals USA, Inc. | 11 | $205 |
| Vanda Pharmaceuticals Inc. | 7 | $189 |
| Jazz Pharmaceuticals Inc. | 3 | $173 |
| H2-pharma, LLC | 1 | $150 |
| Johnson & Johnson | 6 | $118 |
| Lilly USA, LLC | 6 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $112 |
| Almatica Pharma LLC | 3 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Eisai Inc. | 3 | $52 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $47 |
| Bausch Health US, LLC | 2 | $27 |
| Alfasigma USA, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$448,006 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 54 | $454,321 |
| NuplazidPimavanserin Tartrate | 44 | $326,131 |
| WakixPitolisant Hcl | 12 | $192,821 |
| NuedextaDextromethorphan Hbr/Quinidine | 85 | $138,963 |
| RexultiBrexpiprazole | 57 | $123,261 |
| VraylarCariprazine Hcl | 27 | $61,372 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $27,004 |
| TrintellixVortioxetine Hydrobromide | 21 | $18,625 |
| MounjaroTirzepatide | 11 | $13,719 |
| Mirtazapine | 436 | $10,397 |
| Memantine Hcl ErMemantine Hcl | 71 | $9,991 |
| SunosiSolriamfetol Hcl | 12 | $9,865 |
| Seroquel XrQuetiapine Fumarate | 11 | $8,545 |
| SeroquelQuetiapine Fumarate | 18 | $7,336 |
| Divalproex Sodium | 167 | $7,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $411,181 | $454,32154 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,033 | $326,13144 claims |
| Harmony Biosciences LLCWakix | $806 | $192,82112 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $210 | $138,96385 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16,179 | $123,26157 claims |
| AbbVieVraylar | $8,908 | $61,37227 claims |
| Alkermes, Inc.Lybalvi | $786 | $27,00418 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $438 | $18,62521 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $113 | $15,45757 claims |
| Axsome Therapeutics, Inc.Sunosi | $677 | $9,86512 claims |
| Johnson & JohnsonConcerta | $118 | $4,67211 claims |
| Almatica Pharma LLCSertraline Hcl | $69 | $1,699162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Centereach
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.